Payment overview · 2025
General Payments
$240.70
15 reported records · 9 companies
Healthcare provider profile · identity verified
Wally M Werner, MD
Allopathic & Osteopathic Physicians|Internal Medicine · ALCOA, TN · NPI 1780762997
Verified facts
What the public records show
CMS Open Payments records show Wally M Werner, MD received $240.70 in general payments during 2025 across 15 reported records.
AstraZeneca Pharmaceuticals LP accounted for 25.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 17 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Jardiance, Mounjaro, Ozempic, Trelegy Ellipta.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Jardiance by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 121 claims for Eliquis by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 63 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $61.84 | 25.7% | 4 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $52.48 | 21.8% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $39.13 | 16.3% | 2 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $17.54 | 7.3% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $15.51 | 6.4% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $13.61 | 5.7% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $13.57 | 5.6% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $13.51 | 5.6% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $13.51 | 5.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $240.70 | 15 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $45.23 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $39.13 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $33.96 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $18.64 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $18.52 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $18.52 | 1 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $17.54 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $16.61 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C. | $15.51 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $13.61 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $13.61 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $13.57 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $13.57 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $13.51 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $13.51 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $13.51 | 1 | 2025 |
Source payment records
|
|||||
| VAXNEUVANCE Normalized: vaxneuvance |
Biological | Merck Sharp & Dohme LLC | $13.51 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 121 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 40 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 43 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 63 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 25 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
40 | 12 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
121 | 29 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
40 | 12 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
43 | 11 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
63 | 18 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 459 | 122 |
| Levothyroxine Sodium | Levothyroxine Sodium | 373 | 90 |
| Amlodipine Besylate | Amlodipine Besylate | 274 | 78 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 253 | 68 |
| Omeprazole | Omeprazole | 234 | 59 |
| Gabapentin | Gabapentin | 216 | 52 |
| Alprazolam | Alprazolam | 204 | 31 |
| Tamsulosin Hcl | Tamsulosin Hcl | 198 | 49 |
| Losartan Potassium | Losartan Potassium | 190 | 49 |
| Lisinopril | Lisinopril | 174 | 42 |
| Pantoprazole Sodium | Pantoprazole Sodium | 155 | 41 |
| Hydrochlorothiazide | Hydrochlorothiazide | 153 | 44 |
| Metoprolol Succinate | Metoprolol Succinate | 148 | 43 |
| Trazodone Hcl | Trazodone Hcl | 144 | 30 |
| Metformin Hcl | Metformin Hcl | 134 | 33 |
| Escitalopram Oxalate | Escitalopram Oxalate | 122 | 30 |
| Eliquis | Apixaban | 121 | 29 |
| Simvastatin | Simvastatin | 119 | 32 |
| Duloxetine Hcl | Duloxetine Hcl | 115 | 25 |
| Potassium Chloride | Potassium Chloride | 112 | 36 |
| Benazepril Hcl | Benazepril Hcl | 106 | 27 |
| Valsartan | Valsartan | 106 | 26 |
| Metoprolol Tartrate | Metoprolol Tartrate | 103 | 30 |
| Famotidine | Famotidine | 97 | 27 |
| Montelukast Sodium | Montelukast Sodium | 90 | 25 |
| Metformin Hcl Er | Metformin Hcl | 79 | 22 |
| Carvedilol | Carvedilol | 75 | 17 |
| Clopidogrel | Clopidogrel Bisulfate | 75 | 20 |
| Allopurinol | Allopurinol | 74 | 21 |
| Sertraline Hcl | Sertraline Hcl | 72 | 17 |
| Spironolactone | Spironolactone | 69 | 22 |
| Telmisartan | Telmisartan | 69 | 19 |
| Citalopram Hbr | Citalopram Hydrobromide | 67 | 16 |
| Tramadol Hcl | Tramadol Hcl | 65 | 13 |
| Lorazepam | Lorazepam | 64 | suppressed |
| Methocarbamol | Methocarbamol | 64 | 26 |
| Ozempic | Semaglutide | 63 | 18 |
| Doxycycline Hyclate | Doxycycline Hyclate | 62 | 54 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 62 | 16 |
| Furosemide | Furosemide | 60 | 22 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 60 | 19 |
| Pravastatin Sodium | Pravastatin Sodium | 58 | 14 |
| Fenofibrate | Fenofibrate | 56 | 11 |
| Glimepiride | Glimepiride | 53 | 14 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 52 | 14 |
| Diazepam | Diazepam | 52 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 52 | 15 |
| Pregabalin | Pregabalin | 51 | 11 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 49 | 14 |
| Prednisone | Prednisone | 49 | 33 |
| Quetiapine Fumarate | Quetiapine Fumarate | 49 | 14 |
| Bupropion Hcl Sr | Bupropion Hcl | 48 | 13 |
| Dutasteride | Dutasteride | 48 | 13 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 48 | 13 |
| Donepezil Hcl | Donepezil Hcl | 47 | 14 |
| Fluticasone Propionate | Fluticasone Propionate | 46 | 11 |
| Ezetimibe | Ezetimibe | 45 | 11 |
| Mounjaro | Tirzepatide | 43 | 11 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 41 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 41 | 12 |
| Jardiance | Empagliflozin | 40 | 12 |
| Ondansetron Odt | Ondansetron | 40 | 21 |
| Lovastatin | Lovastatin | 38 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 38 | suppressed |
| Mirtazapine | Mirtazapine | 37 | suppressed |
| Torsemide | Torsemide | 37 | 16 |
| Doxazosin Mesylate | Doxazosin Mesylate | 36 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 35 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 34 | suppressed |
| Myrbetriq | Mirabegron | 34 | suppressed |
| Finasteride | Finasteride | 33 | suppressed |
| Nabumetone | Nabumetone | 33 | 13 |
| Ropinirole Hcl | Ropinirole Hcl | 32 | 12 |
| Tizanidine Hcl | Tizanidine Hcl | 32 | suppressed |
| Baclofen | Baclofen | 31 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 31 | 25 |
| Linzess | Linaclotide | 31 | suppressed |
| Nystatin | Nystatin | 31 | 15 |
| Celecoxib | Celecoxib | 30 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 30 | suppressed |
| Atenolol | Atenolol | 29 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 29 | suppressed |
| Cevimeline Hcl | Cevimeline Hcl | 27 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 27 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 27 | suppressed |
| Ramipril | Ramipril | 27 | suppressed |
| Fluconazole | Fluconazole | 26 | 14 |
| Memantine Hcl | Memantine Hcl | 26 | suppressed |
| Methylprednisolone | Methylprednisolone | 26 | 15 |
| Amitriptyline Hcl | Amitriptyline Hcl | 25 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 25 | suppressed |
| Meloxicam | Meloxicam | 25 | suppressed |
| Nitroglycerin | Nitroglycerin | 25 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 25 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 24 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 24 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 24 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 23 | 12 |
| Oxycodone Hcl | Oxycodone Hcl | 23 | suppressed |
| Cefdinir | Cefdinir | 22 | 22 |
| Dicyclomine Hcl | Dicyclomine Hcl | 22 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 22 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 21 | suppressed |
| Estradiol | Estradiol | 20 | suppressed |
| Glipizide | Glipizide | 20 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 19 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 19 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 18 | suppressed |
| Verapamil Er | Verapamil Hcl | 18 | suppressed |
| Bupropion Xl | Bupropion Hcl | 17 | suppressed |
| Clonazepam | Clonazepam | 17 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 17 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 17 | suppressed |
| Indapamide | Indapamide | 16 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 16 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 16 | suppressed |
| Xarelto | Rivaroxaban | 16 | suppressed |
| Azithromycin | Azithromycin | 15 | 14 |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 15 | 12 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 15 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 15 | suppressed |
| Acyclovir | Acyclovir | 14 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 14 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 14 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 13 | suppressed |
| Bumetanide | Bumetanide | 13 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 13 | suppressed |
| Ibuprofen | Ibuprofen | 13 | suppressed |
| Metronidazole | Metronidazole | 13 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 13 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 13 | suppressed |
| Repatha Sureclick | Evolocumab | 13 | suppressed |
| Butalb-Acetaminoph-Caff-Codein | Butalbit/Acetamin/Caff/Codeine | 12 | suppressed |
| Chlorthalidone | Chlorthalidone | 12 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Januvia | Sitagliptin Phosphate | 12 | suppressed |
| Lansoprazole | Lansoprazole | 12 | suppressed |
| Levemir Flexpen | Insulin Detemir | 12 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 12 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 12 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 11 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 11 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 11 | suppressed |
| Eszopiclone | Eszopiclone | 11 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 11 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $240.70 · 15 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, AREXVY, CAPVAXIVE, ELIQUIS, FARXIGA, GARDASIL 9, GVOKE HYPOPEN, JARDIANCE, MOUNJARO, OTEZLA, Ozempic, REPATHA, Rybelsus, SHINGRIX, TRELEGY ELLIPTA, VAXNEUVANCE, ZEPBOUND | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error